VTVT Logo

vTv Therapeutics Inc. (VTVT) 

NASDAQ
Market Cap
$40.9M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
797 of 809
Rank in Industry
439 of 445

Largest Insider Buys in Sector

VTVT Stock Price History Chart

VTVT Stock Performance

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Insider Activity of vTv Therapeutics Inc.

Over the last 12 months, insiders at vTv Therapeutics Inc. have bought $0 and sold $0 worth of vTv Therapeutics Inc. stock.

On average, over the past 5 years, insiders at vTv Therapeutics Inc. have bought $9.18M and sold $100,050 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 40,461 shares for transaction amount of $33,773 was made by FRY JOHN A (director) on 2022‑11‑29.

List of Insider Buy and Sell Transactions, vTv Therapeutics Inc.

2022-11-29PurchaseFRY JOHN Adirector
40,461
0.0852%
$0.83$33,773-9.63%
2022-11-28PurchaseFRY JOHN Adirector
20,539
0.0431%
$0.83$16,969-8.98%
2021-12-20SalePERELMAN RONALD Odirector
87,000
0.154%
$1.15$100,050-26.54%
2021-02-26PurchaseNelson Rich S.director
60,000
0.1142%
$2.86$171,600-31.58%
2021-02-26PurchaseKOZLOV HERSHdirector
10,000
0.0182%
$2.74$27,400-31.58%
2020-12-17PurchasePERELMAN RONALD Odirector
625,000
0.9225%
$1.60$1M-2.36%
2020-12-10PurchasePERELMAN RONALD Odirector
625,000
0.893%
$1.60$1M-4.79%
2020-11-24PurchasePERELMAN RONALD Odirector
625,000
1.0514%
$1.60$1M+13.44%
2020-05-15PurchaseKOZLOV HERSHdirector
10,000
0.022%
$3.00$30,000-22.48%
2020-05-12PurchasePERELMAN RONALD Odirector
625,000
0.8555%
$1.60$1M-8.98%
2020-02-25PurchasePERELMAN RONALD Odirector
1.25M
1.438%
$1.60$2M-33.44%
2020-01-28PurchasePERELMAN RONALD Odirector
1.25M
2.1109%
$1.60$2M-2.29%
2020-01-07PurchasePERELMAN RONALD Odirector
1.25M
2.5998%
$1.60$2M+20.34%
2019-12-18PurchasePERELMAN RONALD Odirector
1.37M
4.3437%
$1.46$2M+40.13%
2019-11-26PurchasePERELMAN RONALD Odirector
1.37M
4.4914%
$1.46$2M+42.86%
2019-11-12PurchasePERELMAN RONALD Odirector
1.37M
4.3437%
$1.46$2M+38.16%
2019-10-24PurchasePERELMAN RONALD Odirector
1.37M
4.2053%
$1.46$2M+33.76%
2019-09-26PurchasePERELMAN RONALD Odirector
1.37M
4.3232%
$1.46$2M+45.83%
2019-09-18PurchasePERELMAN RONALD Odirector
606,061
1.8097%
$1.65$1M+22.09%
2019-09-13PurchaseKOZLOV HERSHdirector
5,000
0.0159%
$1.65$8,250+30.03%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
No records found…